Balyasny Asset Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Balyasny Asset Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-943	Closed	-$67K	–	2204
2018 Q2	$67K	Sell	943 -3,857	-80%	-$272K	﹤0.01%	1726
2018 Q1	$295K	Sell	4,800 -17,141	-78%	-$1.5M	﹤0.01%	1624
2017 Q4	$2.77M	Buy	21,941 +6,195	+39%	+$793K	0.01%	1049
2017 Q3	$2.15M	Buy	15,746 +3,431	+28%	+$459K	0.01%	940
2017 Q2	$1.76M	Buy	12,315 +1,440	+13%	+$223K	0.01%	959
2017 Q1	$2M	Buy	+10,875	New	+$1.22M	0.01%	909
2015 Q3	–	Sell	-280	Closed	-$266K	–	1480
2015 Q2	$266K	Buy	+280	New	+$229K	﹤0.01%	973

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Balyasny Asset Management's TTPH Position: Q3 2018 in Review

Balyasny Asset Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2018, closing a stake of 943 shares — an estimated $67K sold.

Balyasny Asset Management first reported a position in TTPH in Q2 2015 and held it in 7 quarters. The position peaked at $2.77M in Q4 2017. 92 funds tracked by Wall St. Rank hold TTPH as of Q3 2018.

Balyasny Asset Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Balyasny Asset Management sold 943 Tetraphase Pharmaceuticals, Inc. shares in Q3 2018, an estimated $67K.
Balyasny Asset Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
Balyasny Asset Management's Tetraphase Pharmaceuticals, Inc. position peaked at $2.77M in Q4 2017.
92 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.